{"url_path":"/sec/bcli/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062648-index.html","accession_number":"0001104659-26-062648","cik":"0001137883","ticker":"BCLI","issuer_name":"BRAINSTORM CELL THERAPEUTICS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1137883/0001104659-26-062648-index.html","primary_entity_key":"0001137883","primary_entity_name":"BRAINSTORM CELL THERAPEUTICS INC."},"word_count":1314,"has_tables":true,"body_markdown":"BRAINSTORM CELL THERAPEUTICS INC._March  31, 2026\n\n0001137883--12-312026Q1false11125536000255360002553600022589000225890002258900022589000225890001811111110001137883us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001137883bcli:AtMarketOfferingMember2021-08-092021-08-090001137883us-gaap:TreasuryStockCommonMember2026-03-310001137883us-gaap:RetainedEarningsMember2026-03-310001137883us-gaap:AdditionalPaidInCapitalMember2026-03-310001137883us-gaap:TreasuryStockCommonMember2025-12-310001137883us-gaap:RetainedEarningsMember2025-12-310001137883us-gaap:AdditionalPaidInCapitalMember2025-12-310001137883us-gaap:TreasuryStockCommonMember2025-03-310001137883us-gaap:RetainedEarningsMember2025-03-310001137883us-gaap:AdditionalPaidInCapitalMember2025-03-310001137883us-gaap:TreasuryStockCommonMember2024-12-310001137883us-gaap:RetainedEarningsMember2024-12-310001137883us-gaap:AdditionalPaidInCapitalMember2024-12-310001137883us-gaap:CommonStockMember2026-03-310001137883us-gaap:CommonStockMember2025-12-310001137883us-gaap:CommonStockMember2025-03-310001137883us-gaap:CommonStockMember2024-12-310001137883us-gaap:EmployeeStockOptionMember2025-12-310001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2025-06-250001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2025-06-240001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2024-09-160001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2025-06-252025-06-250001137883us-gaap:RestrictedStockMember2025-01-012025-12-310001137883us-gaap:RestrictedStockMember2025-12-310001137883bcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2023-07-172023-07-170001137883us-gaap:RetainedEarningsMember2026-01-012026-03-310001137883us-gaap:RetainedEarningsMember2025-01-012025-03-3100011378832025-01-012025-12-310001137883us-gaap:RestrictedStockMember2026-03-310001137883us-gaap:EmployeeStockOptionMember2026-03-310001137883us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2026-05-112026-05-1100011378832025-11-100001137883us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2026-05-110001137883bcli:ShortTermLoanAgreementMember2025-12-240001137883bcli:ShortTermLoanAgreementMember2025-12-150001137883bcli:ShortTermLoanAgreementMember2025-10-310001137883bcli:ShortTermLoanAgreementMember2025-10-060001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2026-03-310001137883bcli:UnregisteredWarrantsMemberbcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2024-06-270001137883bcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2024-06-270001137883bcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2023-07-1700011378832025-03-3100011378832024-12-310001137883us-gaap:RestrictedStockMember2026-01-012026-03-310001137883us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001137883us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001137883us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001137883us-gaap:RestrictedStockMember2025-01-012025-03-310001137883us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001137883us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001137883us-gaap:EmployeeStockOptionMember2025-01-012025-03-3100011378832025-12-3100011378832026-05-110001137883bcli:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2026-02-280001137883bcli:PreFundedWarrantsMemberbcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2024-06-2700011378832026-03-310001137883us-gaap:PrivatePlacementMember2026-02-012026-02-280001137883us-gaap:PrivatePlacementMember2026-02-280001137883us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001137883us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001137883us-gaap:CommonStockMember2025-01-012025-03-310001137883bcli:AtMarketOfferingMember2026-01-012026-03-3100011378832026-01-012026-03-3100011378832025-01-012025-03-310001137883bcli:SingleReportableSegmentMember2026-01-012026-03-310001137883bcli:SingleReportableSegmentMember2025-01-012025-03-310001137883us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberbcli:SecuritiesPurchaseAgreementMember2026-05-112026-05-110001137883us-gaap:ConvertibleNotesPayableMember2025-12-312025-12-310001137883us-gaap:ConvertibleNotesPayableMember2025-12-310001137883us-gaap:ConvertibleNotesPayableMember2026-01-060001137883bcli:ConvertiblePromissoryNoteIssuedOnNovember202025Member2025-11-202025-11-200001137883srt:MinimumMemberus-gaap:ConvertibleNotesPayableMember2025-12-310001137883srt:MaximumMemberus-gaap:ConvertibleNotesPayableMember2025-12-310001137883us-gaap:ConvertibleNotesPayableMember2026-01-052026-01-050001137883bcli:ConvertiblePromissoryNoteIssuedOnNovember102025Member2025-11-102025-11-100001137883bcli:ConvertiblePromissoryNoteIssuedOnOctober312025Member2025-10-312025-10-310001137883us-gaap:ConvertibleNotesPayableMember2026-01-062026-01-060001137883us-gaap:ConvertibleNotesPayableMember2026-01-050001137883bcli:ConvertiblePromissoryNoteIssuedOnNovember202025Member2025-11-200001137883bcli:ConvertiblePromissoryNoteIssuedOnNovember102025Member2025-11-100001137883bcli:ConvertiblePromissoryNoteIssuedOnOctober312025Member2025-10-310001137883us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberbcli:SecuritiesPurchaseAgreementMember2026-05-110001137883bcli:CommonWarrantsMemberus-gaap:PrivatePlacementMember2026-02-280001137883bcli:PublicOfferingMemberbcli:SecuritiesPurchaseAgreementMember2024-06-272024-06-270001137883bcli:GlobalShareOptionPlan2014AndUsStockOptionAndIncentivePlan2014Member2024-09-162024-09-16xbrli:pureiso4217:USDbcli:securitybcli:itembcli:installmentxbrli:sharesbcli:agreementiso4217:USDxbrli:sharesbcli:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n(Mark One)\n\n​\n\n**☒**\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n​\n\nFor the quarterly period ended March  31, 2026.\n\nor\n\n​\n\n**☐**\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n​\n\nFor the transition period from _____________ to _____________\n\nCommission File Number 001-36641\n\n**BRAINSTORM CELL THERAPEUTICS INC.**\n\n(Exact name of registrant as specified in its charter)\n\n​\n\nDelaware\n\n20-7273918\n\n(State or other jurisdiction of\n\n(I.R.S. Employer\n\nincorporation or organization)\n\nIdentification No.)\n\n​\n\n1325 Avenue of Americas, 28th Floor\n\n \n\nNew York, NY\n\n10019\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n​\n\n(201) 488-0460\n\n(Registrant’s telephone number, including area code)\n\nNot Applicable\n\n(Former name, former address and former fiscal year, if changed since last report)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon Stock, $0.00005 par value\n\nBCLI\n\nOTCQB Venture Market\n(OTCQB)\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceeding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer ☐\n\n​\n\nAccelerated filer ☐\n\n​\n\nNon-accelerated filer ☒\n\n​\n\nSmaller reporting company ☒\n\n​\n\n​\n\nEmerging growth company ☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒\n\nAs of May 11, 2026, the number of shares outstanding of the registrant’s Common Stock, $0.00005 par value per share, was 11,034,775.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**\n\n*This quarterly report contains numerous statements, descriptions, forecasts and projections, regarding Brainstorm Cell Therapeutics Inc. (together with its consolidated subsidiaries, the “Company,” “Brainstorm,” “we,” “us” or “our”) and its potential future business operations and performance, including financial results for the most recent fiscal quarter, statements regarding the market potential for treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (“ALS”), the sufficiency of our existing capital resources for continuing operations in 2026 and beyond, the safety and clinical effectiveness of our NurOwn® technology, our clinical trials of NurOwn® and its related clinical development, and our ability to develop collaborations and partnerships to support our business plan. In some cases you can identify such “forward-looking statements” by the use of words like “may,” “will,” “should,” “could,” “expects,” “hopes,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” “goals,” “estimates,” “predicts,” “likely,” “potential,” or “continue” or the negative of any of these terms or similar words. These statements, descriptions, forecasts and projections constitute “forward-looking statements,” and as such involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance and achievements to be materially different from any results, levels of activity, performance and achievements expressed or implied by any such “forward-looking statements.” These risks and uncertainties include, but are not limited to the potential consequences of our delisting from The Nasdaq Stock Market (the “Nasdaq”) and our common stock trading on the OTCQB Venture Market on the liquidity and price of our common stock; the outcomes of the putative securities class action and derivative lawsuits filed by five of our shareholders, the potential for more derivative lawsuits to be brought, our need to raise additional capital, our ability to continue as a going concern, regulatory approval of our NurOwn® treatment candidate, the success of our product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of our NurOwn® treatment candidate to achieve broader acceptance as a treatment option for ALS, progressive multiple sclerosis (“PMS”), Alzheimer’s disease(“AD”) or other neurodegenerative diseases, our ability to manufacture and commercialize our NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, our ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation, adverse developments affecting the financial services industry, political instability, unrest and wars, such as the conflicts involving Ukraine and Russia and Israel and its surrounding regions, including our clinical development activities, our ability to improve our internal control over financial reporting, including our inability to remediate the identified material weakness, as well as the costs and the time associated with such efforts, and other factors described under “Risk Factors” in this report and in our annual report on Form 10-K for the fiscal year ended December 31, 2025. These “forward-looking statements” are based on certain assumptions that we have made as of the date hereof. To the extent these assumptions are not valid, the associated “forward-looking statements” and projections will not be correct. Although we believe that the expectations reflected in these “forward-looking statements” are reasonable, we cannot guarantee any future results, levels of activity, performance, or achievements. It is routine for our internal projections and expectations to change as the year or each quarter in the year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which we base our expectations may change prior to the end of each quarter or the year. Although these expectations may change, we may not inform you if they do and we undertake no obligation to do so, except as required by applicable securities laws and regulations. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. In evaluating our business, prospective investors should carefully consider the information set forth under the caption “Risk Factors” in this report and in our annual report on Form 10-K for the fiscal year ended December 31, 2025 in addition to the other information set forth herein and elsewhere in our other public filings with the Securities and Exchange Commission (“SEC”).*\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\nTABLE OF CONTENTS\n\n​\n\n​\n\n**  ​ ​ ​**\n\n​\n\n**Page********Number**\n\n[PART I – FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_932654)\n\n4\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1FinancialStatements_864544)\n\n​\n\n[Financial Statements](#Item1FinancialStatements_864544)\n\n4\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysisofF)\n\n​\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n22\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n[Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n38\n\n[Item 4.](#Item4ControlsandProcedures_259239)\n\n​\n\n[Controls and Procedures](#Item4ControlsandProcedures_259239)\n\n38\n\n​\n\n​\n\n​\n\n​\n\n[PART II – OTHER INFORMATION](#PARTIIOTHERINFORMATION_292926)\n\n38\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1LegalProceedings_142777)\n\n​\n\n[Legal Proceedings](#Item1LegalProceedings_142777)\n\n38\n\n[Item 1A.](#Item1ARiskFactors_805047)\n\n​\n\n[Risk Factors](#Item1ARiskFactors_805047)\n\n40\n\n[Item 5.](#Item5OtherInformation_524549)\n\n​\n\n[Other Information](#Item5OtherInformation_524549)\n\n42\n\n[Item 6.](#Item6Exhibits_774170)\n\n​\n\n[Exhibits](#Item6Exhibits_774170)\n\n43\n\n​\n\n​\n\n​\n\n​\n\n[SIGNATURES](#SIGNATURES_282494)\n\n44\n\n​\n\n​\n\n​\n\n3\n\n[Table of Contents](#TOC)\n\n**PART I – FINANCIAL INFORMATION**"}